Himalaya Nutravedics India Limited · BSE:HNIL
Himalaya Nutravedics India — Investor Presentation (October 2026)
25 slides from Himalaya Nutravedics India's investor presentation, Oct 3, 2026
Slide 1: Himalaya Nutravedics India Limited Investor Presentation FY26
HIMALAYA NUTRAVEDICS INDIA LIMITED Investor Presentation - FY26
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation is for information purposes only and does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase any securities ("Securities") of Himalaya Nutravedics India limited (or the ”company") in India or any other juris
Slide 3: Agenda
Agenda 01 Executive Summary 02 About Himalaya Nutravedics India Ltd. 03 Comprehensive Product Portfolio 04 Industry Landscape 05 Competitive MOATS 06 Investment Rationale 07 Financial Performance
Slide 4: Executive Summary
Executive Summary Revenue from Operations Cashflow from Operations Debt Service Coverage Ratio ₹ 4,306.8 lakhs YoY +105.1% ₹ - 383.4 lakhs ( vs ₹ - 139.1 lakhs 92.5x +355.8% in FY25) EBITDA EBITDA Margin Inventory Turnover Ratio ₹ 810.3 lakhs YoY +171.0% 18.8% +458 bps 4.3x - 0.2x PAT PAT Margin Tra
Slide 5: About the Company
About the Company Himalaya Nutravedics India Limited is an integrated ayurvedic and nutraceutical company engaged in the manufacturing, marketing and distribution of a diversified portfolio of classical Particulars (In ₹ Lakhs) FY26 FY25 FY24 (Shastric ) ayurvedic formulations, proprietary ayurvedic
Slide 6: Our Journey
Our Journey • Incorporated as Himalaya Nutravedics • Further expanded market presence to Uttar India Private Limited Pradesh, Jharkhand and Delhi • Commenced commercial manufacturing operations from the Hyderabad facility • Achieved ISO 22000 :2018 , ISO 9001 :2015 and WHO - GMP certifications • Ent
Slide 7: Business Model
Business Model Our Brand Business Own - Brand Portfolio Classification Classical Ayurvedic Prescription - led, doctor engagement driven offline sales model . Nature: Traditional medicines Basis of Formulation: Multi - tier distribution via Super -Stockists, Stockists, and Retail Established ayurvedi
Slide 8: Management Commentary
Management Commentary Himalaya Nutravedics India Limited has steadily evolved into an integrated ayurvedic and nutraceutical company, engaged in the manufacturing, marketing and distribution of ayurvedic formulations and nutraceutical products, alongside providing third - party contract manufacturin
Slide 9: Leadership Team
Leadership Team ROHIT ASAWA DIVYA ASAWA Chairman & Managing Director (Promoter Group) Non - Executive Director (Promoter Group) Rohit Asawa holds a degree in Electronics and Communication Divya Asawa holds a degree in Commerce from Osmania University and Engineering from Jawaharlal Nehru Technologic
Slide 10: Product Portfolio
Product Portfolio Product Category Key Focus Areas Pain Management & Musculoskeletal Care - Medicated oils, gels, and targeted anti - inflammatory oral doses . Digestive & Gut Health - Classical and proprietary formulations for Gastrointestinal support . Softgel Capsules Medicated Oils Hardgel Capsu
Slide 11: Proprietary Portfolio - Ayurvedic
Proprietary Portfolio - Ayurvedic Orthopedic & Pain Chronic & Lifestyle Gastrointestinal & Men's Health & Specialty Management Diseases Liver Health Vitality Care Comprehensive care for Targeted management for Formulations for gut health, Specialized care for male Focused treatments across arthritis
Slide 12: Nutraceutical Product Portfolio
Nutraceutical Product Portfolio Coqrite - plus Tablets Lythimin Tablets Lythmin Plus Tablets Coqrite Tablets Key Actives : Astaxanthin, Key Actives : Omega - 3 Fatty Acids Key Actives : Multivitamins, Key Actives : Coenzyme Q 10, Coenzyme Q 10, Elemental Zinc, (DHA & EPA), Essential Multivitamins Mu
Slide 13: Pan-India Reach Through a Diversified Distribution Network
Pan - India Reach Through a Diversified Distribution Network Pan - India Distribution Network Distribution Footprint • Products reach 17 states across India through a multi - tier network of super stockists, stockists, and retailers . • Deep penetration in key markets : Kerala, Gujarat, Uttar Prades
Slide 14: Historical Performance (1/2)
Historical Performance (1/2) Revenue from Operations (In ₹ Lakhs) EBITDA (In ₹ Lakhs) Profit After Tax (PAT) (In ₹ Lakhs) 810.3 739.0 4,306.8 2,099.7 299.0 1,442.6 223.2 93.5 42.6 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 EPS (In ₹) EBITDA Margin (In %) PAT Margin (In %) 18.8% 24.8 17.2% 14.2% 18
Slide 15: Historical Performance (2/2)
Historical Performance (2/2) ROE (In %) ROCE (In %) Debt - to - Equity (In Times) 63.9% 36.4% 55.0% 30.2% 2.4 37.3% 17.0% 0.3 0.3 FY24 FY25 FY26 FY24 FY25 FY26 FY24 FY25 FY26 Net Worth (In ₹ Lakhs) Return On Net Worth (In %) Current Ratio (In Times) 1,637.6 45.1% 2.7 2.8 31.8% 33.1% 674.8 1.1 134.1
Slide 16: Operational Metrics
Operational Metrics Product Segment Mix (%) Capacity Utilization (%) 1 Geographic Footprint Business Segment Mix (%) 100 % 90% 5.4% 90% 7.9% 20.7% 80% 31.1% 70% 64% 50.7% 54.4% 48.9% 60% 56% 72.0% 50% 80.4% 92.1% 94.6% 40% 34% 79.3% 29% 30% 68.9% 49.3% 51.1% 20% 45.6% 10% 28.0% 19.7% 10% 0% FY24 FY2
Slide 17: Industry Growth Drivers
Industry Growth Drivers Healthcare Spending % of GDP Industry Tailwinds & Drivers • The nutraceutical, ayurvedic, and wellness products industry in India is experiencing a structural shift in consumer behavior towards digital platforms . • Consumers today increasingly rely on digital channels, inclu
Slide 18: Industry Growth Drivers
Industry Growth Drivers Industry Tailwinds & Drivers Product Segment Market Forecast 2024 –35 (USD billion) • High - Growth Trajectory for Herbal & Vitamin Segments : There is a strong structural demand for natural and plant - based formulations . Status as of 2024 Projected by 2035 • The herbal pro
Slide 19: Competitive Moats
Competitive Moats Integrated Manufacturing Practitioner - Driven Diversified Therapeutic Rapid Geographic Enduring Ecosystem & Capabilities Prescription Model Coverage Scale Supply Chain • WHO - GMP & ISO Certified • Healthcare Professional • Comprehensive Portfolio : • Pan - India Footprint with •
Slide 20: Strategic Growth Plan
Strategic Growth Plan 4. Deepening Geographic Reach & Export Readiness 3. Expanding Own - Branded The Company aims to deepen its domestic footprint beyond its existing 16 States and 1 Portfolio & High - Margin SKUs Union Territory by strengthening its multi - Building on the growth of its proprietar
Slide 21: Investment Rationale
Investment Rationale Positioned in High - Growth Nutraceutical & Ayurvedic Segments Himalaya Nutravedics operates across two fast - growing wellness segments ayurvedic formulations and nutraceutical supplements —catering to therapeutic areas such as orthopedic care, metabolic disorders, gastroentero
Slide 22: Income Statement
Income Statement ₹ Lakhs Unless Otherwise Mentioned Particulars FY26 FY25 YoY change (%) FY24 Revenue from Operations 4,306.8 2,099.7 105.1% 1,442.6 Cost of materials consumed including finished goods and WIP 2,606.2 1,296.6 101.0% 846.7 Employee benefits expense 276.4 293.5 (5.8%) 302.4 Other expen
Slide 23: Balance Sheet
Balance Sheet ₹ Lakhs Unless Otherwise Mentioned Assets FY26 FY25 FY24 Property plant & equipment 96.0 120.5 140.9 Capital WIP 0.0 0.0 0.0 Long term loans & advances - - - Other non - current assets ( incl intangible assets & non - current investments) 176.2 48.9 10.7 Inventories 891.5 328.4 252.3 T
Slide 24: Cash Flow Statement
Cash Flow Statement ₹ Lakhs Unless Otherwise Mentioned Particulars FY26 FY25 FY24 Net cash from / (used in) operating activities (383.4) (139.1) (55.1) Net cash from / (used in) investing activities (5.8) (22.6) (109.8) Net cash from / (used in) financing activities 527.1 143.9 184.2 Net Increase /
Slide 25: Thank You
Thank You For any further information/factory visit request, please contact: Company Himalaya Nutravedics India Limited [email protected] Investor Relations Consultant Capital Bridge Advisory Service Private Ltd Rishi Kothari Krisha Anandpara [email protected] [email protected] +91 - 8
Himalaya Nutravedics India — Investor Presentation (October 2026) on 6ix